Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temtokibart in Healthy Subjects and Atopic Dermatitis
NCT03514511Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- May 2018
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of temtokibart in atopic dermatitis (AD) (9 cohorts), sponsored by LEO Pharma. Primary endpoints: Number of subjects with adverse events, Number of adverse events and 1 more. Started May 2018; status: completed.
02
Drugs
temtokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03514511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514511.